Digital Pathology Market by Product( ArtificiaI Intelligence, Scanner, Software, Storage), Type(Human, Veterinary), Application( Teleconsultation, Training, Disease Diagnosis, Drug Discovery), End User( Pharma, Academia, Hospitals ) - Global Forecast to 2026
[257 Pages Report] The global digital pathology market is valued at an estimated USD 736 million in 2021 and is projected to reach USD 1,371 million by 2026, at a CAGR of 13.2% during the forecast period. The growth in the digital pathology market is mainly driven by factors such as the increasing adoption of digital pathology to enhance lab efficiency, rising incidence of cancer, and growing applications of digital pathology in drug development and companion diagnostics.
To know about the assumptions considered for the study, Request for Free Sample Report
Covid-19 Impact on the Digital Pathology Market
Amidst the growing number of cases and deaths due to COVID-19, various solution providers are collaborating with healthcare institutions, like hospital laboratories and other laboratory facilities, to deal with the increasing number of tests coming to laboratories for COVID-19 screening and diagnosis.
Regulatory authorities like the FDA are relaxing their regulations temporarily to encourage the use of digital pathology solutions. For instance, the agency decided to relax its regulation in the last week of March to reduce the immediate risk of the virus to pathologists. The agency does not intend to object to modifications to already cleared digital pathology devices to allow for remote use or the marketing of new remote digital pathology devices without submitting a 510(k), so long as the devices do not create undue risk. For instance, Leica Biosystems received notification from the US FDA in 2020 to exercise enforcement discretion for using Aperio WebViewer for remote diagnosis with the help of images obtained from Aperio AT2 or Aperio AT2 DX digital pathology scanners during the COVID-19 emergency. Philips also received notification from the US FDA to exercise enforcement discretion for using Philips IntelliSite Pathology Solution for pathologists who can review pathological cases remotely during the COVID-19 emergency.
With the COVID-19 pandemic, most countries, including Europe, the US, India, and Australia, followed a complete lockdown. This lockdown and restrictions related to social distancing led to an increase in the use of digital pathology solutions that help in remote access to diagnostic tests performed in CLIA-certified laboratories. The sales of digital pathology scanners and storages decreased in 2019-2020 owing to a lack of interactions required for the demonstration of devices to clients and a lower number of pathological tests conducted in the laboratories. However, the demand for digital pathology solutions has increased after 2020. They help facilitate the continuity of patient care, reduce the risk of healthcare professionals being exposed to coronavirus, and prevent disruption of critical pathology services.
Digital Pathology Market Dynamics
Driver: Increasing adoption of digital pathology to enhance lab efficiency
Digital pathology helps improve lab efficiency by reducing costs, decreasing turnaround times, and providing users with access to subject-matter expertise. Improvements in lab efficiency are critical as patients and physicians are dependent on lab results for diagnostic decisions, and diagnostic tests are required to be completed and reported quickly & accurately. Moreover, access to digital slides via web services eliminate shipping costs and travel time for pathologists. The outbreak of the COVID-19 pandemic has led to the implementation of lockdowns and social distancing restrictions. Such restrictions have increased the demand for digital pathology solutions, as pathologists can use these to view diagnostic results for primary diagnosis remotely.
Restraint: High cost of digital pathology systems
A typical digital pathology system, which includes a slide scanner, an image server, and software, costs around USD 500,000 to USD 700,000. The average price of a digital pathology scanner in the Asia Pacific is around USD 110,000 to USD 130,000. Although large hospitals with significant capital budgets can afford these systems, pathologists and academic institutes with limited budgets or IT support often cannot afford them. Healthcare providers, particularly in developing countries like India, Brazil, and Mexico, have low financial resources to invest in such costly technologies. Moreover, trained staff is required for the efficient handling and maintenance of digital pathology systems. The high cost of these systems, coupled with the challenge of a dearth of skilled personnel to operate digital pathology systems, is expected to limit the adoption of these systems.
Opportunity: Introduction of affordable scanners for private pathology practices
The price point of digital pathology hardware, including scanners, is a major restraint to market growth. Therefore, the development of affordable scanners is expected to offer growth opportunities for players operating in the digital pathology market. Most private medical practices are small businesses and cannot afford expensive digital pathology systems. The introduction of affordable scanners and the propensity of small players to move towards digitization of pathology workflow will encourage its adoption among pathologists with low or limited budgets.
Challenges: Shortage of trained pathologists
Pathologists play a crucial role in performing laboratory tests essential for disease diagnosis. However, there is a gap between the supply and demand of pathologists worldwide, especially in Africa and the Asia Pacific region countries. According to a Springer study (2020), Switzerland's number of inhabitants per pathologist is 35,355; in Canada and the US, this number is 20,658 and 25,325, respectively. In Germany, there is one pathologist per 47,989 inhabitants.
Digital pathology enables medical practitioners to remotely share important information with pathologists beyond geographical boundaries securely and timely. Moreover, advanced technologies, such as AI and machine learning, helps pathologists identify diseases faster and help improve their efficacy and efficiency. Thus, the alarming shortage of pathologists is expected to result in the increased utilization of digital pathology for providing remote pathological consultation and services.
The scanners segment accounted for the largest share of the Digital Pathology market in 2020.
Based on products, the digital pathology market has been segmented into scanners, software, and storage systems. The large share of the scanners segment can be attributed to the high price of scanners and the increasing adoption of digital pathology solutions.
The human pathology segment accounted for the largest share of the Digital Pathology market in 2020
Based on type, the global digital pathology market is segmented into human pathology and veterinary pathology. The human pathology segment accounted for the largest share of the digital pathology market in 2020. This is due to the increasing number of cancer research activities and growing collaborations among research institutes, universities, and pathology laboratories.
The drug discovery, segment accounted for the largest share of the Digital Pathology market in 2020.
Based on application, the digital pathology market is segmented into drug discovery, disease diagnosis, and training & education. The drug discovery segment accounted for the largest share of the digital pathology market in 2020. Growth in R&D expenditure fueled by the need for numerous preclinical and clinical studies performed during the drug discovery and development process is a major factor responsible for market growth.
The pharmaceutical & biotechnology companies, segment accounted for the largest share of the Digital Pathology market in 2020.
Based on end users, the global digital pathology market is segmented into pharmaceutical & biotechnology companies, hospitals & reference laboratories, and academic & research institutes. The pharmaceutical & biotechnology companies segment accounted for the largest share of the digital pathology market in 2020. The large share of this segment can be attributed to the increasing use of digital pathology for drug discovery studies and drug toxicology testing. Biotechnology companies also use digital pathology for biobanking, biopharmaceutical studies, molecular assays, and the development of individualized medicine.
To know about the assumptions considered for the study, download the pdf brochure
The market in North America is projected to witness the highest growth rate during the forecast period (2021–2026)
North America accounted for the largest share of the digital pathology market in 2020. The increasing prevalence of cancer, rising demand for quality diagnostics, the introduction of favorable reimbursement policies, and the implementation of favorable initiatives by the governments in the US and Canada are major factors driving the growth of the digital pathology market in North America
Key Market Players
The major players in the global Digital Pathology market are Leica Biosystems (US), Koninklijke Philips N.V. (Netherlands), Hamamatsu Photonics (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), 3DHISTECH (Hungary), Apollo Enterprise Imaging (US), XIFIN, Inc. (US), Huron Digital Pathology (Canada), Visiopharm A/S (Denmark), Aiforia Technologies Oy (Finland), Akoya Biosciences (US), Corista (US), Indica Labs (US), Objective Pathology Services (Canada), Sectra AB (Sweden), OptraSCAN (US), Glencoe Software (US), KONFOONG BIOTECH INTERNATIONAL CO., LTD. (China), Inspirata, Inc. (US), PathAI (US), Proscia Inc. (US), Kanteron Systems (Spain), Mikroscan Technologies (US), Motic (US), and Paige (US).
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
|
Report Metric |
Details |
|
Market size available for years |
2019–2026 |
|
Base year considered |
2020 |
|
Forecast period |
2021–2026 |
|
Forecast units |
Value (USD) |
|
Segments covered |
Product, type, application, end-user and region |
|
Geographies covered |
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
|
Companies covered |
|
The research report categorizes the Digital Pathology market into the following segments and subsegments:
Product
- Scanners
- Brightfield
- Other Scanners
- Software
- Integrated Software
- Standalone Software
- Information Management Software
- Image Analysis Software
- Storage Systems
Type
- Human Pathology
- Veterinary Pathology
Application
- Drug Discovery
- Disease Diagnosis
- Training & Education
End User
- Pharmaceutical & Biotechnology Companies
- Hospitals and Reference Laboratories
- Academic & Research Institutes
Region
- North America
- US
- Canada
- Europe
- France
- Germany
- UK
- Sweden
- Denmark
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
Recent Developments
- In September 2021, Visiopharm (Denmark) and Agilent Technologies, Inc. (US) collaborated to co-market Visiopharm’s portfolio of CE-IVD marked AI-driven Precision Pathology software and Agilent’s automated pathology staining solutions portfolio.
- In August 2021, Sectra AB (Sweden) and University Medical Center Utrecht (Netherlands) signed an agreement under which UMC uses Sectra’s pathology module for effective multidisciplinary discussions among pathologists and radiologists.
- In May 2021, Sectra AB (Sweden) and Institut Curie (France) signed an agreement which allows the digitization of pathology at Institut Curie. The pathologists in Institut Curie can access cases, digital tools, and AI applications through the Sectra pathology solution.
- In April 2021, Leica Biosystems (US) and Paige.AI, Inc. (US) partnered for Paige’s AI-enabled research software for tumor detection, grading, and quantification to Leica Biosystems digital pathology platform in countries throughout North America and Europe.
- In August 2020, Leica Biosystems (US) and Bio-Techne Corporation (US) partnered to automate RNAscope COVID-19 probes on Leica’s BOND RX platform for research use. This helps reduce manual labor and turnaround time.
Frequently Asked Questions (FAQ):
Which are the top industry players in the global Digital Pathology market?
The top market players in the Digital Pathology market include Leica Biosystems (US), Koninklijke Philips N.V. (Netherlands), Hamamatsu Photonics (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), 3DHISTECH (Hungary), Apollo Enterprise Imaging (US), XIFIN, Inc. (US), Huron Digital Pathology (Canada), Visiopharm A/S (Denmark), Aiforia Technologies Oy (Finland), Akoya Biosciences (US), Corista (US), Indica Labs (US), Objective Pathology Services (Canada), and Sectra AB (Sweden).
Which Digital Pathology products have been included in this report?
This report includes the following products:
- Product
- Scanners
- Brightfield
- Other Scanners
- Software
- Integrated Software
- Standalone Software
- Information Management Software
- Image Analysis Software
- Storage Systems
Which geographical region is dominating the Digital Pathology market?
The global Digital Pathology market is segmented into North America, Europe, Asia Pacific, and Latin Ameica and Middle East & Africa. North America accounted for the largest share of the Digital Pathology market in 2020. Factors such the increasing prevalence of cancer, rising demand for quality diagnostics, the introduction of favorable reimbursement policies, and the implementation of favorable initiatives by the governments in the US and Canada are driving the growth of the digital pathology market in North America..
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 24)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS OF THE STUDY
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 29)
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.1.2.2 Insights from primary experts
2.1.2.3 Breakdown of primary sources
2.2 MARKET SIZE ESTIMATION
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 MARKET SHARE ESTIMATION
2.5 ASSUMPTIONS FOR THE STUDY
2.6 RISK ASSESSMENT
2.7 MARKET LIMITATIONS
2.7.1 METHODOLOGY-RELATED LIMITATIONS
2.7.2 SCOPE-RELATED LIMITATIONS
3 EXECUTIVE SUMMARY (Page No. - 41)
4 PREMIUM INSIGHTS (Page No. - 45)
4.1 DIGITAL PATHOLOGY MARKET OVERVIEW
4.2 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER & COUNTRY (2020)
4.3 DIGITAL PATHOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.4 REGIONAL MIX: DIGITAL PATHOLOGY MARKET (2021–2026)
4.5 DIGITAL PATHOLOGY MARKET: DEVELOPING VS. DEVELOPED MARKETS
5 MARKET OVERVIEW (Page No. - 49)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing adoption of digital pathology to enhance lab efficiency
5.2.1.2 Rising incidence of cancer
5.2.1.3 Growing applications of digital pathology in drug development and companion diagnostics
5.2.2 RESTRAINTS
5.2.2.1 High cost of digital pathology systems
5.2.3 OPPORTUNITIES
5.2.3.1 Introduction of affordable scanners for private pathology practices
5.2.3.2 Growing demand for personalized medicine
5.2.3.3 High growth opportunities in emerging economies
5.2.4 CHALLENGES
5.2.4.1 Shortage of trained pathologists
5.3 COVID-19 IMPACT ANALYSIS
5.3.1 IMPACT OF COVID-19 ON THE DIGITAL PATHOLOGY MARKET
5.4 ECOSYSTEM MARKET MAP
5.5 TRENDS IN AVERAGE SELLING PRICE
5.6 IMPACT OF THE NEW IVD REGULATION ON DIFFERENT MARKETS
5.6.1 IMPACT ON CLINICAL LAB SERVICES
5.6.2 IMPACT ON IVD
5.6.3 IMPACT ON DIGITAL PATHOLOGY
5.7 TECHNOLOGY ANALYSIS
5.7.1 ARTIFICIAL INTELLIGENCE (AI) IN DIGITAL PATHOLOGY
5.8 PATENT ANALYSIS
5.8.1 METHODOLOGY
5.8.2 PUBLICATION TRENDS
5.8.3 JURISDICTION ANALYSIS
5.8.4 TOP APPLICANTS
6 DIGITAL PATHOLOGY MARKET, BY PRODUCT (Page No. - 64)
6.1 INTRODUCTION
6.2 SCANNERS
6.2.1 SCANNERS ACCOUNTED FOR THE LARGEST SHARE OF THE DIGITAL PATHOLOGY PRODUCTS MARKET IN 2020
6.2.1.1 Brightfield scanners
6.2.1.2 Other scanners
6.3 SOFTWARE
6.3.1 INTEGRATED SOFTWARE
6.3.1.1 Integrated software segment to dominate the market during the forecast period
6.3.2 STANDALONE SOFTWARE
6.3.2.1 Information management software
6.3.2.1.1 Information management software enables comprehensive integration with any institute’s information systems
6.3.2.2 Image analysis software
6.3.2.2.1 Image analysis software provides easy-to-use solutions for the quantitative evaluation of brightfield slides
6.4 STORAGE SYSTEMS
6.4.1 REQUIREMENT FOR THE SAFE AND RELIABLE STORAGE OF HIGH-QUALITY IMAGES TO ENSURE MARKET GROWTH
7 DIGITAL PATHOLOGY MARKET, BY TYPE (Page No. - 82)
7.1 INTRODUCTION
7.2 HUMAN PATHOLOGY
7.2.1 THE COVID-19 PANDEMIC HAS LED TO AN INCREASING DEMAND FOR DIGITAL PATHOLOGY SOLUTIONS
7.3 VETERINARY PATHOLOGY
7.3.1 VETERINARY DIGITAL PATHOLOGY REDUCES THE TURNAROUND TIME FOR ANIMAL DISEASE DIAGNOSIS─KEY FACTOR DRIVING THE MARKET GROWTH
8 DIGITAL PATHOLOGY MARKET, BY APPLICATION (Page No. - 86)
8.1 INTRODUCTION
8.2 DRUG DISCOVERY
8.2.1 INCREASING R&D SPENDING TO DRIVE THE GROWTH OF THIS SEGMENT
8.3 DISEASE DIAGNOSIS
8.3.1 USE OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DIGITAL PATHOLOGY SOLUTIONS FOR DIAGNOSTIC PURPOSES TO DRIVE MARKET GROWTH
8.4 TRAINING & EDUCATION
8.4.1 DIGITAL PATHOLOGY CAN IMPROVE EDUCATION & TRAINING PROVIDED TO PATHOLOGISTS IN ACADEMIC INSTITUTES
9 DIGITAL PATHOLOGY MARKET, BY END USER (Page No. - 95)
9.1 INTRODUCTION
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ARE THE LARGEST & FASTEST-GROWING END USERS OF THE DIGITAL PATHOLOGY MARKET
9.3 HOSPITALS & REFERENCE LABORATORIES
9.3.1 INCREASING ADOPTION OF DIGITAL PATHOLOGY SOLUTIONS IN HOSPITALS TO DRIVE THE GROWTH OF THIS SEGMENT
9.4 ACADEMIC & RESEARCH INSTITUTES
9.4.1 FUNDING INVESTMENTS AND INITIATIVES TO BOOST THE GROWTH OF THIS END-USER SEGMENT IN THE DIGITAL PATHOLOGY MARKET
10 DIGITAL PATHOLOGY MARKET, BY REGION (Page No. - 106)
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 US
10.2.1.1 Favorable reimbursement scenario for digital pathology in the US to drive the adoption of digital pathology solutions
10.2.2 CANADA
10.2.2.1 Cancer awareness initiatives by the government to drive the market growth in Canada
10.3 EUROPE
10.3.1 UK
10.3.1.1 The UK is the largest market for digital pathology in Europe owing to rising government funding & initiatives
10.3.2 GERMANY
10.3.2.1 High healthcare expenditure and supportive health insurance in Germany to drive the adoption of digital pathology solutions
10.3.3 SWEDEN
10.3.3.1 Increasing government initiatives for the deployment of digital pathology solutions to drive the market growth in Sweden
10.3.4 DENMARK
10.3.4.1 High prevalence of cancer to support the market growth in Denmark
10.3.5 FRANCE
10.3.5.1 Increasing government funding and favorable insurance system are the major factors responsible for the rising adoption of digital pathology solutions in France
10.3.6 REST OF EUROPE (ROE)
10.4 ASIA PACIFIC (APAC)
10.4.1 CHINA
10.4.1.1 Favorable initiatives by the government for the adoption of telepathology in China
10.4.2 JAPAN
10.4.2.1 Universal healthcare reimbursement is driving the adoption of digital pathology solutions in Japan
10.4.3 INDIA
10.4.3.1 Growing number of cancer cases in India to drive market growth
10.4.4 REST OF ASIA PACIFIC (ROAPAC)
10.5 LATIN AMERICA
10.5.1 BRAZIL
10.5.1.1 Growing geriatric population and the subsequent increase in age-related disorders to drive the adoption of digital pathology solutions in Brazil
10.5.2 MEXICO
10.5.2.1 Rising burden of infectious diseases to drive the uptake of digital pathology in Mexico
10.5.3 REST OF LATIN AMERICA (ROLATAM)
10.6 MIDDLE EAST & AFRICA
10.6.1 INFRASTRUCTURAL DEVELOPMENTS IN THE REGION TO BOOST THE ADOPTION OF TECHNOLOGICALLY ADVANCED PATHOLOGY SOLUTIONS
11 COMPETITIVE LANDSCAPE (Page No. - 185)
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT-TO-WIN
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
11.4 COMPETITIVE BENCHMARKING
11.5 COMPETITIVE LEADERSHIP MAPPING
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.6 COMPETITIVE LEADERSHIP MAPPING FOR OTHER COMPANIES
11.6.1 PROGRESSIVE COMPANIES
11.6.2 DYNAMIC COMPANIES
11.6.3 STARTING BLOCKS
11.6.4 RESPONSIVE COMPANIES
11.7 MARKET SHARE ANALYSIS
11.8 COMPETITIVE SCENARIO
11.8.1 PRODUCT LAUNCHES AND APPROVALS
11.8.2 DEALS
12 COMPANY PROFILES (Page No. - 200)
12.1 KEY PLAYERS
12.1.1 LEICA BIOSYSTEMS
12.1.1.1 Business overview
12.1.1.2 Products & services offered
12.1.1.3 Recent developments
12.1.1.4 MnM view
12.1.1.4.1 Right-to-win
12.1.1.4.2 Strategic choices made
12.1.1.4.3 Weaknesses and competitive threats
12.1.2 KONINKLIJKE PHILIPS N.V.
12.1.2.1 Business overview
12.1.2.2 products & services Offered
12.1.2.3 Recent developments
12.1.2.4 MnM view
12.1.2.4.1 Right-to-win
12.1.2.4.2 Strategic choices made
12.1.2.4.3 Weaknesses and competitive threats
12.1.3 HAMAMATSU PHOTONICS
12.1.3.1 Business overview
12.1.3.2 Products & Services Offered
12.1.3.3 Recent developments
12.1.3.4 MnM view
12.1.3.4.1 Right-to-win
12.1.3.4.2 Strategic choices made
12.1.4 F. HOFFMANN-LA ROCHE LTD.
12.1.4.1 Business overview
12.1.4.2 Products offered
12.1.4.3 Recent developments
12.1.4.4 MnM view
12.1.4.4.1 Right-to-win
12.1.4.4.2 Strategic choices made
12.1.5 SECTRA AB
12.1.5.1 Business overview
12.1.5.2 Products offered
12.1.5.3 Recent developments
12.1.5.4 MnM view
12.1.5.4.1 Right-to-win
12.1.5.4.2 Strategic choices made
12.1.6 AKOYA BIOSCIENCES
12.1.6.1 Business overview
12.1.6.2 Products offered
12.1.6.3 Recent developments
12.1.7 3DHISTECH
12.1.7.1 Business overview
12.1.7.2 Products offered
12.1.7.3 Recent developments
12.1.8 APOLLO ENTERPRISE IMAGING CORP.
12.1.8.1 Business overview
12.1.8.2 Products offered
12.1.8.3 Recent developments
12.1.9 XIFIN, INC.
12.1.9.1 Business overview
12.1.9.2 Products offered
12.1.9.3 Recent developments
12.1.10 HURON DIGITAL PATHOLOGY
12.1.10.1 Business overview
12.1.10.2 Products offered
12.1.10.3 Recent developments
12.1.11 VISIOPHARM
12.1.11.1 Business overview
12.1.11.2 Products offered
12.1.11.3 Recent developments
12.1.12 CORISTA
12.1.12.1 Business overview
12.1.12.2 Products offered
12.1.12.3 Recent developments
12.1.13 INDICA LABS
12.1.13.1 Business overview
12.1.13.2 Products offered
12.1.13.3 Recent developments
12.1.14 OBJECTIVE PATHOLOGY SERVICES
12.1.14.1 Business overview
12.1.14.2 Products offered
12.1.15 OPTRASCAN, INC.
12.1.15.1 Business overview
12.1.15.2 Products offered
12.1.15.3 Recent developments
12.1.16 GLENCOE SOFTWARE, INC.
12.1.16.1 Business overview
12.1.16.2 Products offered
12.1.17 AIFORIA TECHNOLOGIES OY
12.1.17.1 Business overview
12.1.17.2 Products offered
12.1.17.3 Recent developments
12.1.18 PAIGE
12.1.18.1 Business overview
12.1.18.2 Products offered
12.1.18.3 Recent developments
12.1.19 INSPIRATA, INC.
12.1.19.1 Business overview
12.1.19.2 Products offered
12.1.19.3 Recent developments
12.1.20 PROSCIA, INC.
12.1.20.1 Business overview
12.1.20.2 Products offered
12.1.20.3 Recent developments
12.2 OTHER PLAYERS
12.2.1 PATHAI
12.2.2 KONFOONG BIOTECH INTERNATIONAL CO., LTD.
12.2.3 MIKROSCAN TECHNOLOGIES, INC.
12.2.4 MOTIC DIGITAL PATHOLOGY
12.2.5 KANTERON SYSTEMS
13 APPENDIX (Page No. - 250)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
LIST OF TABLES (279 Tables)
TABLE 1 RISK ASSESSMENT: DIGITAL PATHOLOGY MARKET
TABLE 2 GLOBAL CANCER INCIDENCE, 2018 VS. 2025
TABLE 3 US: GROWTH IN THE NUMBER OF PERSONALIZED MEDICINES (2008–2020)
TABLE 4 NUMBER OF INHABITANTS PER PATHOLOGIST, BY COUNTRY, 2020
TABLE 5 DIGITAL PATHOLOGY AI MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 6 DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 7 SCANNING MAGNIFICATION AND APPLICATIONS
TABLE 8 DIGITAL PATHOLOGY SCANNERS OFFERED BY KEY MARKET PLAYERS
TABLE 9 DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 10 DIGITAL PATHOLOGY SCANNERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 11 DIGITAL PATHOLOGY SCANNERS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 12 DIGITAL PATHOLOGY SCANNERS MARKET, BY REGION, 2019–2026 (UNITS)
TABLE 13 BRIGHTFIELD SCANNERS OFFERED BY KEY MARKET PLAYERS
TABLE 14 BRIGHTFIELD SCANNERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 15 OTHER SCANNERS OFFERED BY KEY MARKET PLAYERS
TABLE 16 OTHER SCANNERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 17 DIGITAL PATHOLOGY SOFTWARE OFFERED BY KEY MARKET PLAYERS
TABLE 18 DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 19 DIGITAL PATHOLOGY SOFTWARE MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 20 INTEGRATED SOFTWARE OFFERED BY KEY MARKET PLAYERS
TABLE 21 INTEGRATED SOFTWARE MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 22 STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 23 STANDALONE SOFTWARE MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 24 INFORMATION MANAGEMENT SOFTWARE OFFERED BY KEY MARKET PLAYERS
TABLE 25 INFORMATION MANAGEMENT SOFTWARE MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 26 IMAGE ANALYSIS SOFTWARE OFFERED BY KEY MARKET PLAYERS
TABLE 27 IMAGE ANALYSIS SOFTWARE MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 28 STORAGE SYSTEMS OFFERED BY KEY MARKET PLAYERS
TABLE 29 STORAGE SYSTEMS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 30 DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 31 HUMAN DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 32 VETERINARY DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 33 DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 34 PRODUCT CROSSED MAPPING FOR DIFFERENT APPLICATIONS
TABLE 35 DIGITAL PATHOLOGY SCANNERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 36 DIGITAL PATHOLOGY SCANNERS MARKET, BY APPLICATION, 2019–2026 (UNITS)
TABLE 37 APPLICATIONS OF DIGITAL PATHOLOGY IN DRUG DISCOVERY
TABLE 38 DIGITAL PATHOLOGY MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 39 DIGITAL PATHOLOGY SCANNERS MARKET FOR DRUG DISCOVERY, BY REGION, 2019–2026 (USD MILLION)
TABLE 40 DIGITAL PATHOLOGY SCANNERS MARKET FOR DRUG DISCOVERY, BY REGION, 2019–2026 (UNITS)
TABLE 41 DIGITAL PATHOLOGY MARKET FOR DISEASE DIAGNOSIS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 42 DIGITAL PATHOLOGY SCANNERS MARKET FOR DISEASE DIAGNOSIS, BY REGION, 2019–2026 (USD MILLION)
TABLE 43 DIGITAL PATHOLOGY SCANNERS MARKET FOR DISEASE DIAGNOSIS, BY REGION, 2019–2026 (UNITS)
TABLE 44 DIGITAL PATHOLOGY MARKET FOR TRAINING & EDUCATION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 45 DIGITAL PATHOLOGY SCANNERS MARKET FOR TRAINING & EDUCATION, BY REGION, 2019–2026 (USD MILLION)
TABLE 46 DIGITAL PATHOLOGY SCANNERS MARKET FOR TRAINING & EDUCATION, BY REGION, 2019–2026 (UNITS)
TABLE 47 DIGITAL PATHOLOGY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 48 PRODUCT CROSSED MAPPING FOR DIFFERENT END USERS
TABLE 49 DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 50 DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (UNITS)
TABLE 51 DIGITAL PATHOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 52 DIGITAL PATHOLOGY SCANNERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 53 DIGITAL PATHOLOGY SCANNERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2026 (UNITS)
TABLE 54 HOSPITAL DEPLOYMENT OF DIGITAL PATHOLOGY SOLUTIONS
TABLE 55 DIGITAL PATHOLOGY MARKET FOR HOSPITALS & REFERENCE LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 56 DIGITAL PATHOLOGY SCANNERS MARKET FOR HOSPITALS & REFERENCE LABORATORIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 57 DIGITAL PATHOLOGY SCANNERS MARKET FOR HOSPITALS & REFERENCE LABORATORIES, BY REGION, 2019–2026 (UNITS)
TABLE 58 DIGITAL PATHOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 59 DIGITAL PATHOLOGY SCANNERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2019–2026 (USD MILLION)
TABLE 60 DIGITAL PATHOLOGY SCANNERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2019–2026 (UNITS)
TABLE 61 DIGITAL PATHOLOGY MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 62 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 63 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 64 NORTH AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 65 NORTH AMERICA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 66 NORTH AMERICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 67 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 68 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 69 NORTH AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 70 NORTH AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY APPLICATION, 2019–2026 (UNITS)
TABLE 71 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 72 NORTH AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 73 NORTH AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (UNITS)
TABLE 74 US: CANCER INCIDENCE RATE, 2020
TABLE 75 US: DIGITAL PATHOLOGY CONFERENCES
TABLE 76 US: KEY MACROINDICATORS
TABLE 77 US: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 78 US: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 79 US: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 80 US: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 81 US: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 82 US: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 83 US: DIGITAL PATHOLOGY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 84 CANADA: CANCER INCIDENCE RATE, 2020
TABLE 85 CANADA: DIGITAL PATHOLOGY INITIATIVES AND FUNDING
TABLE 86 CANADA: KEY MACROINDICATORS
TABLE 87 DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 88 CANADA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 89 CANADA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 90 CANADA: DIGITAL PATHOLOGY STANDLONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 91 CANADA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 92 CANADA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 93 CANADA: DIGITAL PATHOLOGY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 94 EUROPE: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 95 EUROPE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 96 EUROPE: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 97 EUROPE: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 98 EUROPE: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 99 EUROPE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 100 EUROPE: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 101 EUROPE: DIGITAL PATHOLOGY SCANNERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 102 EUROPE: DIGITAL PATHOLOGY SCANNERS MARKET, BY APPLICATION, 2019–2026 (UNITS)
TABLE 103 EUROPE: DIGITAL PATHOLOGY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 104 EUROPE: DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 105 EUROPE: DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (UNITS)
TABLE 106 CONFERENCES/COURSES HELD IN THE UK
TABLE 107 UK: KEY MACROINDICATORS
TABLE 108 UK: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 109 UK: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 110 UK: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 111 UK: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 112 UK: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 113 UK: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 114 UK: DIGITAL PATHOLOGY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 115 GERMANY: CANCER INCIDENCE RATE, 2020
TABLE 116 GERMANY: KEY MACROINDICATORS
TABLE 117 GERMANY: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 118 GERMANY: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 119 GERMANY: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 120 GERMANY: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 121 GERMANY: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 122 GERMANY: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 123 GERMANY: DIGITAL PATHOLOGY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 124 SWEDEN: CANCER INCIDENCE RATE, 2020
TABLE 125 SWEDEN: KEY MACROINDICATORS
TABLE 126 SWEDEN: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026(USD MILLION)
TABLE 127 SWEDEN: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 128 SWEDEN: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 129 SWEDEN: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 130 SWEDEN: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 131 SWEDEN: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 132 SWEDEN: DIGITAL PATHOLOGY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 133 DENMARK: CANCER INCIDENCE RATE, 2020
TABLE 134 DENMARK: KEY MACROINDICATORS
TABLE 135 DENMARK: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 136 DENMARK: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 137 DENMARK: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 138 DENMARK: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 139 DENMARK: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 140 DENMARK: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 141 DENMARK: DIGITAL PATHOLOGY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 142 FRANCE: CANCER INCIDENCE RATE, 2020
TABLE 143 FRANCE: KEY MACROINDICATORS
TABLE 144 FRANCE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 145 FRANCE: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 146 FRANCE: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 147 FRANCE: DIGITAL PATHOLOGY STANDLONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 148 FRANCE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 149 FRANCE: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 150 FRANCE: DIGITAL PATHOLOGY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 151 ROE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 152 ROE: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 153 ROE: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 154 ROE: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 155 ROE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 156 ROE: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 157 ROE: DIGITAL PATHOLOGY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 158 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 159 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 160 ASIA PACIFIC: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 161 ASIA PACIFIC: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 162 ASIA PACIFIC: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 163 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 164 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 165 ASIA PACIFIC: DIGITAL PATHOLOGY SCANNERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 166 ASIA PACIFIC: DIGITAL PATHOLOGY SCANNERS MARKET, BY APPLICATION, 2019–2026 (UNITS)
TABLE 167 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 168 ASIA PACIFIC: DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 169 ASIA PACIFIC: DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (UNITS)
TABLE 170 CHINA: CANCER INCIDENCE RATE, 2020
TABLE 171 CHINA: KEY MACROINDICATORS
TABLE 172 CHINA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 173 CHINA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 174 CHINA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 175 CHINA: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 176 CHINA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 177 CHINA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 178 CHINA: DIGITAL PATHOLOGY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 179 JAPAN: CANCER INCIDENCE RATE, 2020
TABLE 180 JAPAN: KEY MACROINDICATORS
TABLE 181 JAPAN: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 182 JAPAN: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 183 JAPAN: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 184 JAPAN: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 185 JAPAN: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 186 JAPAN: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 187 JAPAN: DIGITAL PATHOLOGY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 188 INDIA: CANCER INCIDENCE RATE, 2020
TABLE 189 INDIA: KEY MACROINDICATORS
TABLE 190 INDIA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 191 INDIA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 192 INDIA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 193 INDIA: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 194 INDIA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 195 INDIA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 196 INDIA: DIGITAL PATHOLOGY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 197 ROAPAC: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 198 ROAPAC: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 199 ROAPAC: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 200 ROAPAC: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 201 ROAPAC: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 202 ROAPAC: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 203 ROAPAC: DIGITAL PATHOLOGY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 204 LUNG CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES, 2018 VS. 2025
TABLE 205 LIVER CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES, 2018 VS. 2025
TABLE 206 BREAST CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES, 2018 VS. 2025
TABLE 207 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 208 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 209 LATIN AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 210 LATIN AMERICA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 211 LATIN AMERICA: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 212 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 213 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 214 LATIN AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY APPLICATION 2019–2026 (USD MILLION)
TABLE 215 LATIN AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY APPLICATION, 2019–2026 (UNITS)
TABLE 216 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 217 LATIN AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 218 LATIN AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (UNITS)
TABLE 219 BRAZIL: CANCER INCIDENCE RATE, 2020
TABLE 220 BRAZIL: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 221 BRAZIL: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 222 BRAZIL: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 223 BRAZIL: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 224 BRAZIL: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 225 BRAZIL: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 226 BRAZIL: DIGITAL PATHOLOGY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 227 MEXICO: CANCER INCIDENCE RATE, 2020
TABLE 228 MEXICO: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 229 MEXICO: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 230 MEXICO: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 231 MEXICO: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 232 MEXICO: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 233 MEXICO: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 234 MEXICO: DIGITAL PATHOLOGY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 235 ROLATAM: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 236 ROLATAM: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 237 ROLATAM: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 238 ROLATAM: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 239 ROLATAM: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 240 ROLATAM: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 241 ROLATAM: DIGITAL PATHOLOGY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 242 AFRICA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 243 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 244 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 245 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 246 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY STANDALONE SOFTWARE MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 247 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 248 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 249 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 250 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY APPLICATION, 2019–2026 (UNITS)
TABLE 251 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 252 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 253 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY END USER, 2019–2026 (UNITS)
TABLE 254 FOOTPRINT OF COMPANIES IN THE DIGITAL PATHOLOGY MARKET
TABLE 255 PRODUCT: COMPANY FOOTPRINT (25 COMPANIES)
TABLE 256 END USER: COMPANY FOOTPRINT (25 COMPANIES)
TABLE 257 REGION: COMPANY FOOTPRINT (26 COMPANIES)
TABLE 258 KEY PRODUCT LAUNCHES AND APPROVALS
TABLE 259 KEY DEALS
TABLE 260 LEICA BIOSYSTEMS: BUSINESS OVERVIEW
TABLE 261 KONINKLIJKE PHILIPS N.V.: BUSINESS OVERVIEW
TABLE 262 HAMAMATSU PHOTONICS: BUSINESS OVERVIEW
TABLE 263 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
TABLE 264 SECTRA AB: BUSINESS OVERVIEW
TABLE 265 AKOYA BIOSCIENCES: BUSINESS OVERVIEW
TABLE 266 3DHISTECH: BUSINESS OVERVIEW
TABLE 267 APOLLO ENTERPRISE IMAGING CORP.: BUSINESS OVERVIEW
TABLE 268 XIFIN, INC.: BUSINESS OVERVIEW
TABLE 269 HURON DIGITAL PATHOLOGY: BUSINESS OVERVIEW
TABLE 270 VISIOPHARM: BUSINESS OVERVIEW
TABLE 271 CORISTA: BUSINESS OVERVIEW
TABLE 272 INDICA LABS: BUSINESS OVERVIEW
TABLE 273 OBJECTIVE PATHOLOGY SERVICES: BUSINESS OVERVIEW
TABLE 274 OPTRASCAN, INC.: BUSINESS OVERVIEW
TABLE 275 GLENCOE SOFTWARE, INC.: BUSINESS OVERVIEW
TABLE 276 AIFORIA TECHNOLOGIES OY: BUSINESS OVERVIEW
TABLE 277 PAIGE: BUSINESS OVERVIEW
TABLE 278 INSPIRATA, INC.: BUSINESS OVERVIEW
TABLE 279 PROSCIA, INC.: BUSINESS OVERVIEW
LIST OF FIGURES (43 Figures)
FIGURE 1 DIGITAL PATHOLOGY MARKET
FIGURE 2 RESEARCH DESIGN
FIGURE 3 PRIMARY SOURCES
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY CATEGORY, DESIGNATION, AND REGION
FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 7 ILLUSTRATIVE EXAMPLE OF LEICA BIOSYSTEMS (SUBSIDIARY OF DANAHER CORPORATION)
FIGURE 8 SUPPLY-SIDE ANALYSIS: DIGITAL PATHOLOGY MARKET (2020)
FIGURE 9 BOTTOM-UP APPROACH
FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 11 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE DIGITAL PATHOLOGY MARKET (2021–2026)
FIGURE 12 DATA TRIANGULATION METHODOLOGY
FIGURE 13 DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
FIGURE 14 DIGITAL PATHOLOGY MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 15 DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 16 DIGITAL PATHOLOGY MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 17 GEOGRAPHICAL SNAPSHOT OF THE DIGITAL PATHOLOGY MARKET
FIGURE 18 RISING PREVALENCE OF CANCER IS A KEY FACTOR DRIVING MARKET GROWTH
FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN DIGITAL PATHOLOGY MARKET IN 2020
FIGURE 20 MARKET IN THE UK TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
FIGURE 21 NORTH AMERICA TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD (2021–2026)
FIGURE 22 CHINA TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
FIGURE 23 DIGITAL PATHOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 24 IMPACT OF COVID-19 ON THE DIGITAL PATHOLOGY MARKET
FIGURE 25 DIGITAL PATHOLOGY MARKET: ECOSYSTEM MARKET MAP
FIGURE 26 DIGITAL PATHOLOGY MARKET: AVERAGE REGIONAL PRICES OF DIGITAL PATHOLOGY SCANNERS
FIGURE 27 TIMELINE AND TRANSITION TO NEW MDR AND IVDR
FIGURE 28 PUBLICATION TRENDS, 2015–2021
FIGURE 29 JURISDICTION ANALYSIS, 2015–2021
FIGURE 30 TOP APPLICANTS, 2015–2021
FIGURE 31 NORTH AMERICA: DIGITAL PATHOLOGY MARKET SNAPSHOT
FIGURE 32 DENMARK: CANCER PREVALENCE, 2012–2020
FIGURE 33 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE DIGITAL PATHOLOGY MARKET
FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN THE DIGITAL PATHOLOGY MARKET
FIGURE 35 DIGITAL PATHOLOGY MARKET: COMPETITIVE LEADERSHIP MAPPING (2020)
FIGURE 36 DIGITAL PATHOLOGY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR OTHER COMPANIES (2020)
FIGURE 37 DIGITAL PATHOLOGY MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020
FIGURE 38 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
FIGURE 39 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2020)
FIGURE 40 HAMAMATSU PHOTONICS: COMPANY SNAPSHOT (2020)
FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)
FIGURE 42 SECTRA AB: COMPANY SNAPSHOT (2020)
FIGURE 43 AKOYA BIOSCIENCES: COMPANY SNAPSHOT (2020)
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, key players, competitive landscape, key market dynamics, and key player strategies.
Secondary Research
The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the Digital Pathology market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the Digital Pathology market. The primary sources from the demand side included industry experts, purchase & sales managers, doctors, and personnel from research organizations. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.
A breakdown of the primary respondents is provided below:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the Digital Pathology market was arrived at after data triangulation from two different approaches, as mentioned below.
Approach to calculate the revenue of different players in the Digital Pathology market
The size of the global Digital Pathology market was obtained from annual reports, SEC filings, online publications, and extensive primary interviews. A percentage split was applied to arrive at the size of market segments. Further splits were applied to arrive at the size for each sub-segment. These percentage splits were validated by primary participants. The country-level market sizes obtained from the annual reports, SEC filings, online publications, and extensive primary interviews were added up to reach the total market size for regions. By adding up the market sizes for all the regions, the global Digital Pathology market was derived.
Approach to derive the market size and estimate market growth
The market size and market growth were estimated through primary interviews on a regional and global level. All responses were collated, and a weighted average was taken to derive a probabilistic estimate of the market size and growth rate.
Data Triangulation
After arriving at the overall market size-using the market size estimation processes explained above-the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Objectives of the Study
- To define, describe, and forecast the Digital Pathology market based on product, type, application, end user, and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall Digital Pathology market
- To analyze the opportunities in the market for stakeholders and provide details of
- the competitive landscape for market leaders
- To profile the key players in the market and comprehensively analyze their market shares and core competencies
- To forecast the size of the market segments with respect to four main regions, namely,
- North America, the Asia Pacific, Europe, Latin America, and Middle East & Africa.
- To track and analyze competitive developments such as new product launches, agreements, collaborations, and expansions.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographic Analysis
- Further breakdown of the Rest of Asia Pacific digital pathology market into South Korea, Australia, New Zealand, and other countries
- Further breakdown of the Rest of Europe digital pathology market into Italy, Spain, Belgium, Russia, the Netherlands, Switzerland, and other countries
- Further breakdown of the Rest of Latin America digital pathology market into Argentina, Chile, Peru, Colombia, and Cuba.
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Digital Pathology Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Digital Pathology Market